1867 related articles for article (PubMed ID: 20433217)
21. Effect of Diabetes Treatment-Related Attributes on Costs to Type 2 Diabetes Patients in a Real-World Population.
Meng J; Casciano R; Lee YC; Stern L; Gultyaev D; Tong L; Kitio-Dschassi B
J Manag Care Spec Pharm; 2017 Apr; 23(4):446-452. PubMed ID: 28345434
[TBL] [Abstract][Full Text] [Related]
22. Effect of V-Go Versus Multiple Daily Injections on Glycemic Control, Insulin Use, and Diabetes Medication Costs Among Individuals with Type 2 Diabetes Mellitus.
Raval AD; Nguyen MH; Zhou S; Grabner M; Barron J; Quimbo R
J Manag Care Spec Pharm; 2019 Oct; 25(10):1111-1123. PubMed ID: 31556817
[TBL] [Abstract][Full Text] [Related]
23. Medical costs of managed care in patients with type 2 diabetes mellitus.
Bhattacharyya SK; Else BA
Clin Ther; 1999 Dec; 21(12):2131-42. PubMed ID: 10645758
[TBL] [Abstract][Full Text] [Related]
24. Potential short-term economic benefits of improved glycemic control: a managed care perspective.
Menzin J; Langley-Hawthorne C; Friedman M; Boulanger L; Cavanaugh R
Diabetes Care; 2001 Jan; 24(1):51-5. PubMed ID: 11194241
[TBL] [Abstract][Full Text] [Related]
25. Utilization and costs for compliant patients initiating therapy with pioglitazone or rosiglitazone versus insulin in a Medicaid fee-for-service population.
Kalsekar I; Iyer S; Mody R; Rajagopalan R; Kavookjian J
J Manag Care Pharm; 2006 Mar; 12(2):121-9. PubMed ID: 16515370
[TBL] [Abstract][Full Text] [Related]
26. Health care resource utilization associated with a diabetes center and a general medicine clinic.
Huang ES; Gleason S; Gaudette R; Cagliero E; Murphy-Sheehy P; Nathan DM; Singer DE; Meigs JB
J Gen Intern Med; 2004 Jan; 19(1):28-35. PubMed ID: 14748857
[TBL] [Abstract][Full Text] [Related]
27. Total and component health care costs in a non-Medicare HMO population of patients with and without type 2 diabetes and with and without macrovascular disease.
Gandra SR; Lawrence LW; Parasuraman BM; Darin RM; Sherman JJ; Wall JL
J Manag Care Pharm; 2006 Sep; 12(7):546-54. PubMed ID: 16981800
[TBL] [Abstract][Full Text] [Related]
28. Differences in All-Cause Health Care Utilization and Costs in a Type 2 Diabetes Mellitus Population with and Without a History of Cardiovascular Disease.
Mehta S; Ghosh S; Sander S; Kuti E; Mountford WK
J Manag Care Spec Pharm; 2018 Mar; 24(3):280-290. PubMed ID: 29485954
[TBL] [Abstract][Full Text] [Related]
29. Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes.
Oglesby A; Korves C; Laliberté F; Dennis G; Rao S; Suthoff ED; Wei R; Duh MS
Appl Health Econ Health Policy; 2014 Apr; 12(2):179-90. PubMed ID: 24573911
[TBL] [Abstract][Full Text] [Related]
30. Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics.
Sikirica V; Pliszka SR; Betts KA; Hodgkins P; Samuelson T; Xie J; Erder H; Dammerman R; Robertson B; Wu EQ
J Manag Care Pharm; 2012; 18(9):676-89. PubMed ID: 23206211
[TBL] [Abstract][Full Text] [Related]
31. Associations between statin adherence level, health care costs, and utilization.
Zhao Y; Zabriski S; Bertram C
J Manag Care Spec Pharm; 2014 Jul; 20(7):703-13. PubMed ID: 24967523
[TBL] [Abstract][Full Text] [Related]
32. "Act on Threes" Paradigm for Treatment Intensification of Type 2 Diabetes in Managed Care: Results of a Randomized Controlled Study with an Educational Intervention Targeting Improved Glycemic Control.
Bieszk N; Reynolds SL; Wei W; Davis C; Kamble P; Uribe C
J Manag Care Spec Pharm; 2016 Sep; 22(9):1028-38. PubMed ID: 27579824
[TBL] [Abstract][Full Text] [Related]
33. Economic Burden of Illness Among Patients with Severe Asthma in a Managed Care Setting.
Chastek B; Korrer S; Nagar SP; Albers F; Yancey S; Ortega H; Forshag M; Dalal AA
J Manag Care Spec Pharm; 2016 Jul; 22(7):848-61. PubMed ID: 27348285
[TBL] [Abstract][Full Text] [Related]
34. Incremental cardiovascular costs and resource use associated with diabetes: an assessment of 29,863 patients in the US managed-care setting.
Straka RJ; Liu LZ; Girase PS; DeLorenzo A; Chapman RH
Cardiovasc Diabetol; 2009 Sep; 8():53. PubMed ID: 19781099
[TBL] [Abstract][Full Text] [Related]
35. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
36. The effect of a diabetes collaborative care management program on clinical and economic outcomes in patients with type 2 diabetes.
McAdam-Marx C; Dahal A; Jennings B; Singhal M; Gunning K
J Manag Care Spec Pharm; 2015 Jun; 21(6):452-68. PubMed ID: 26011547
[TBL] [Abstract][Full Text] [Related]
37. Cost of self-monitoring of blood glucose in the United States among patients on an insulin regimen for diabetes.
Yeaw J; Lee WC; Aagren M; Christensen T
J Manag Care Pharm; 2012; 18(1):21-32. PubMed ID: 22235952
[TBL] [Abstract][Full Text] [Related]
38. Association between glycemic control and short-term healthcare costs among commercially insured diabetes patients in the United States.
Aagren M; Luo W
J Med Econ; 2011; 14(1):108-14. PubMed ID: 21241161
[TBL] [Abstract][Full Text] [Related]
39. Healthcare resource utilization and cost among patients with type 1 diabetes in the United States.
Simeone JC; Shah S; Ganz ML; Sullivan S; Koralova A; LeGrand J; Bushman J
J Manag Care Spec Pharm; 2020 Nov; 26(11):1399-1410. PubMed ID: 33119443
[No Abstract] [Full Text] [Related]
40. Community-based care for the specialized management of heart failure: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2009; 9(17):1-42. PubMed ID: 23074521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
